Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Higher doses of BMS's psoriasis candidate hit Phase II efficacy mark

Bristol-Myers Squibb Co. (NYSE:BMY) said four of five doses of BMS-986165 met the primary endpoint in the Phase II IM011-011 trial to treat moderate to severe plaque psoriasis. The compound,

Read the full 302 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE